<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4674">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660802</url>
  </required_header>
  <id_info>
    <org_study_id>206207-020</org_study_id>
    <nct_id>NCT01660802</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of 700 μg dexamethasone Posterior Segment
      Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a  6
      month double-blind period versus sham followed by a  2 month open label period.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Retinal Thickness as assessed by Optical Computer Tomography (OCT)</measure>
    <time_frame>Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescein leakage as assessed by fluorescein angiography (FA)</measure>
    <time_frame>Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>700 μg Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) intravitreal injection in the study eye on Day 1 and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham and 700 μg Dexamethasone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sham Posterior Segment Drug Delivery System administered in the study eye on Day 1 and 700 μg Dexamethasone Posterior Segment Drug Delivery System intravitreal injection at Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>700 μg Dexamethasone</intervention_name>
    <description>700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) intravitreal injection in the study eye at Day 1 and Month 6 or Month 6 only.</description>
    <arm_group_label>700 μg Dexamethasone</arm_group_label>
    <arm_group_label>Sham and 700 μg Dexamethasone</arm_group_label>
    <other_name>Ozurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham Posterior Segment Drug Delivery System administered in the study eye on Day 1.</description>
    <arm_group_label>Sham and 700 μg Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Presence of macular edema defined as macular thickening involving the center of the
        macula due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion
        (CRVO)

        Exclusion Criteria:

          -  History of glaucoma, ocular hypertension or optic nerve head change

          -  Any active bacterial, viral, parasitic, or fungal infections in either eye

          -  Eye surgery, including cataract surgery, and/or laser of any type in the study eye
             within 3 months prior to study start

          -  History of use of intravitreal steroids or any intravitreal injectable drug in the
             study eye within 3 months prior to study start

          -  Use of oral, intravenous, intramuscular, epidural, rectal, or extensive dermal
             steroids within 1 month prior to study start

          -  Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating
             agents within 3 months prior to study start

          -  Use of topical ophthalmic corticosticosteroids within 2 weeks of study start
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
